Company intelligence / Profile preview

SYLKE

California, United Statessylke.com ↗

Ownership: Private
Development stage: Commercial

Overview

SYLKE has developed and commercialized an FDA-cleared silk fibroin-based adhesive wound closure device. Clinical studies demonstrate that the product significantly reduces wound healing complications such as erythema and mechanical skin injury compared to synthetic alternatives like Steri-Strips® or cyanoacrylate mesh. The dressing shows superior adherence with lower rates of detachment and improved patient comfort during postoperative recovery.

Therapeutic areas: OtherDermatologyInfectious Diseases
Modalities: DeviceSilk fibroin-based wound dressing
Industry: Consumable Medical Devices

Beyond the preview

Go deeper on SYLKE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYLKE.

Explore the full profile